

Figure S1 Differential expression and enrichment analyses of DE-NETRGs. (A) Volcano plot and (B) heatmap of 5590 DEGs between the breast cancer and control samples (FDR <0.05 and $|\log_2 FC| \geq 1$). (C) Intersection of DEGs and NETRGs to identify DE-NETRGs. (D) Gene Ontology enrichment analysis performed on DE-NETRGs. Yellow represented biological processes, blue represented cellular components, green represented molecular functions, the outermost circle represented enriched functions, the second circle represented the total number of genes contained in this function, the third circle represented the number of genes enriched in this function, dark purple represented upregulation, light purple represented downregulation, and the inner circle represented the proportion of enriched genes to the total number of genes. (E) Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis of DE-NETRGs. Yellow represented the KEGG pathway. DEGs, differentially expressed genes; DE-NETRGs, differentially expressed neutrophil extracellular traps-related genes; FDR, false discovery rate; FC, fold change; KEGG, Kyoto Encyclopedia of Genes and Genomes; BC, breast cancer; NETs, neutrophil extracellular traps.

https://dx.doi.org/10.21037/tcr-24-1826

Table S1 List of the 37 DE-NETRGs

CAT	KLF2	GSDMD	S100A8
GPBAR1	F3	CTSG	S100A9
CXCL2	ELANE	CD177	MPO
IL33	CAMP	C3	LYZ
TLR4	FGL2	CXCR4	HRG
SOCS3	DNASE1	CCL2	PRTN3
SGK1	SELP	CLEC7A	AZU1
CSF3	SPP1	F2RL2	
IL6	MMP9	CLEC6A	
PF4	TIMP1	KRT10	

DE-NETRGs, differentially expressed neutrophil extracellular traps-related genes.

https://dx.doi.org/10.21037/tcr-24-1826

Table S2 Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis for DE-NETRGs

	ID	Description	GeneRatio	BgRatio	pvalue	p.adjust	qvalue	geneID	Count
hsa04613	hsa04613	Neutrophil extracellular trap formation	10/31	190/8157	1.08E-09	1.18E-07	8.05E-08	7099/1991/820/6403/79792/1511/718/64581/4353/566	10
hsa04657	hsa04657	IL-17 signaling pathway	7/31	94/8157	4.52E-08	2.49E-06	1.69E-06	2920/1440/3569/4318/6347/6279/6280	7
hsa05144	hsa05144	Malaria	5/31	50/8157	1.06E-06	3.90E-05	2.65E-05	7099/1440/3569/6403/6347	5
hsa04061	hsa04061	Viral protein interaction with cytokine and cytokine receptor	5/31	100/8157	3.30E-05	0.000909	0.000617	2920/3569/5196/7852/6347	5
hsa04621	hsa04621	NOD-like receptor signaling pathway	6/31	184/8157	5.59E-05	0.000921	0.000626	2920/7099/3569/820/79792/6347	6
hsa04668	hsa04668	TNF signaling pathway	5/31	112/8157	5.70E-05	0.000921	0.000626	2920/9021/3569/4318/6347	5
hsa05134	hsa05134	Legionellosis	4/31	57/8157	5.86E-05	0.000921	0.000626	2920/7099/3569/718	4
hsa04060	hsa04060	Cytokine-cytokine receptor interaction	7/31	295/8157	9.38E-05	0.00129	0.000876	2920/90865/1440/3569/5196/7852/6347	7
hsa05417	hsa05417	Lipid and atherosclerosis	6/31	215/8157	0.000133	0.001621	0.001101	2920/7099/3569/6403/4318/6347	6
hsa05171	hsa05171	Coronavirus disease - COVID-19	6/31	232/8157	0.000201	0.002212	0.001503	7099/1440/3569/6403/718/6347	6
hsa05323	hsa05323	Rheumatoid arthritis	4/31	93/8157	0.000394	0.00376	0.002554	2920/7099/3569/6347	4
hsa05164	hsa05164	Influenza A	5/31	171/8157	0.000417	0.00376	0.002554	90865/7099/9021/3569/6347	5
hsa05150	hsa05150	Staphylococcus aureus infection	4/31	96/8157	0.000444	0.00376	0.002554	820/6403/718/3858	4
hsa05152	hsa05152	Tuberculosis	5/31	180/8157	0.000528	0.003846	0.002613	7099/3569/820/718/64581	5
hsa05142	hsa05142	Chagas disease	4/31	102/8157	0.000559	0.003846	0.002613	7099/3569/718/6347	4
hsa05146	hsa05146	Amoebiasis	4/31	102/8157	0.000559	0.003846	0.002613	2920/7099/3569/1511	4
hsa04068	hsa04068	FoxO signaling pathway	4/31	131/8157	0.001428	0.009242	0.006279	847/6446/3569/10365	4
hsa04936	hsa04936	Alcoholic liver disease	4/31	142/8157	0.001922	0.011748	0.007982	2920/7099/3569/718	4
hsa04145	hsa04145	Phagosome	4/31	152/8157	0.002465	0.01427	0.009695	7099/718/64581/4353	4
hsa05133	hsa05133	Pertussis	3/31	76/8157	0.002897	0.015931	0.010824	7099/3569/718	3
hsa04610	hsa04610	Complement and coagulation cascades	3/31	85/8157	0.003977	0.020831	0.014153	2152/718/2151	3
hsa04062	hsa04062	Chemokine signaling pathway	4/31	192/8157	0.005692	0.027726	0.018838	2920/5196/7852/6347	4
hsa05202	hsa05202	Transcriptional misregulation in cancer	4/31	193/8157	0.005797	0.027726	0.018838	3569/1991/4318/4353	4
hsa04933	hsa04933	AGE-RAGE signaling pathway in diabetic complications	3/31	100/8157	0.006265	0.028716	0.01951	3569/2152/6347	3
hsa04620	hsa04620	Toll-like receptor signaling pathway	3/31	104/8157	0.006984	0.029548	0.020076	7099/3569/6696	3
hsa04625	hsa04625	C-type lectin receptor signaling pathway	3/31	104/8157	0.006984	0.029548	0.020076	3569/64581/93978	3
hsa04066	hsa04066	HIF-1 signaling pathway	3/31	109/8157	0.007949	0.032385	0.022003	7099/3569/7076	3
hsa04151	hsa04151	PI3K-Akt signaling pathway	5/31	354/8157	0.010021	0.039369	0.026749	7099/6446/1440/3569/6696	5

DE-NETRGs, differentially expressed neutrophil extracellular traps-related genes.

https://dx.doi.org/10.21037/tcr-24-1826



Figure S2 Validation of the predictive performance of the risk score model. (A) Distribution curve of risk scores, survival states, and gene expression within the BRCA cohorts from the TCGA-BRCA internal validation dataset. (B) Kaplan-Meier survival curves comparing overall survival between high-risk and low-risk patient groups in the TCGA-BRCA internal validation dataset. (C) Distribution curve of risk scores, survival states, and gene expression in the BRCA cohorts from the GSE42568 external validation dataset. (D) Kaplan-Meier survival curves comparing overall survival between high-risk and low-risk patient groups in the GSE42568 external validation dataset. (E,F) Time-dependent ROC curves evaluating the predictive performance of the risk score model derived from the TCGA-BRCA internal validation dataset (E) and the GSE42568 external validation dataset (F). TCGA, the cancer genome atlas; BRCA, breast cancer; ROC, receiver operating characteristic.

https://dx.doi.org/10.21037/tcr-24-1826



https://dx.doi.org/10.21037/tcr-24-1826

B



https://dx.doi.org/10.21037/tcr-24-1826



Figure S3 Survival analysis of the risk score. (A) Comparison of clinical characteristics associated with different risk scores. ns, no significance; *, P<0.05; **, P<0.01; ***, P<0.001. (B) Kaplan-Meier survival curves showing overall survival differences between high-risk and low-risk groups.

https://dx.doi.org/10.21037/tcr-24-1826



Figure S4 Immune-related analysis in different risk groups. (A) Comparison of immune score, ESTIMATE score, stromal score, and tumor purity between high- and low-risk groups using violin plots. (B) Scatter plots exploring the correlation between risk score and immune score, ESTIMATE score, stromal score, and tumor purity. (C) Differential expression of immune checkpoint genes between high-risk and low-risk groups. (D) Violin plot comparing the immune phenotype score (IPS) and immune cell cytotoxicity score (CP) between high-risk and low-risk groups. (E) Differential analysis of responder prediction, tumor immune dysfunction and exclusion algorithm (TIDE) score, dysfunction score, and exclusion score between the two risk subgroups. The vertical axis of the Responder prediction graph ranged from –2 to 2, representing the prediction scores for immune responders (Responder) and non-immune responders (False). The vertical axis of the TIDE prediction represented the TIDE prediction scores for the high-risk group and the low-risk group. The vertical axis of the Dysfunction prediction represented the T-cell dysfunction scores for the high and low-risk group. The vertical axis of the Exclusion prediction represented the T-cell exclusion scores for the high and low-risk group. ns, no significance; *, P<0.05; **, P<0.01; ***, P<0.001; ****, P<0.0001.

https://dx.doi.org/10.21037/tcr-24-1826

Table S3 Differential analysis of drug sensitivity between two risk subgroups

	CheckPoint	pvalue.w.check	Low_risk	High_risk	logfc
197	BMS-754807_2171	3.93E-24	1.092437867	1.615270528	0.564224582
178	Sepantronium bromide_1941	1.01E-23	0.025911357	0.018170594	-0.511979025
176	UMI-77_1939	4.30E-22	4.19441841	3.826942543	-0.132278542
40	BI-2536_1086	2.74E-17	1.458415511	1.133088846	-0.364140823
121	ULK1_4989_1733	2.70E-15	3.63600144	3.246816856	-0.163326763
36	Paclitaxel_1080	5.49E-15	0.131849276	0.097278366	-0.438698745
81	Lapatinib_1558	4.96E-14	4.631563546	4.159831957	-0.154974058
179	MIM1_1996	6.18E-14	5.83665237	5.48347428	-0.090050883
198	JQ1_2172	7.14E-14	3.901882247	4.028176365	0.04595661
70	AZD2014_1441	1.74E-13	2.99775478	3.346918411	0.158951008
21	Nutlin-3a (-)_1047	9.20E-13	6.477663424	6.969248348	0.105529558
47	PRIMA-1MET_1131	9.59E-13	6.441112066	6.769862794	0.071816802
72	AZD1332_1463	2.42E-12	5.433260668	5.776592995	0.088400585
5	Docetaxel_1007	2.04E-11	0.020125976	0.016512832	-0.285471216
20	Wee1 Inhibitor_1046	6.91E-11	3.257496652	2.921648733	-0.156980961
19	Doramapimod_1042	7.96E-11	6.390101276	6.551718538	0.036034584
95	AZD5582_1617	1.42E-10	3.633129267	3.17538179	-0.194282634
186	MK-8776_2046	2.24E-10	4.964408888	4.368436056	-0.184505073
175	Savolitinib_1936	3.49E-10	3.979983906	3.755663206	-0.083694904
53	Bortezomib_1191	6.06E-10	0.012788408	0.011272615	-0.182014465
180	WEHI-539_1997	8.46E-10	5.411174341	4.838851126	-0.161277171
118	AZD5991_1720	9.12E-10	6.500915675	5.90175846	-0.139498064
48	Erlotinib_1168	9.77E-10	4.03593967	3.71350137	-0.120124498
6	Gefitinib_1010	1.37E-09	4.916912488	4.524791231	-0.119901449
174	P22077_1933	1.82E-09	6.598376063	6.316715027	-0.062936516
107	Ribociclib_1632	2.85E-09	5.339303344	5.554606091	0.05703309
31	AZD8055_1059	4.79E-09	0.833480175	0.875237471	0.07052662
78	Sapitinib_1549	1.02E-08	5.904871562	5.45705544	-0.113782979
127	Ibrutinib_1799	1.09E-08	6.731278251	6.238106161	-0.10977239
177	WIKI4_1940	1.36E-08	5.511099536	5.30034886	-0.056252865
80	LCL161_1557	1.39E-08	7.238878126	7.004350869	-0.047514773
151	MG-132_1862	1.43E-08	0.282797495	0.259967459	-0.121438296
123	Selumetinib_1736	2.46E-08	6.010361413	6.08232883	0.01717207
12	AZD7762_1022	7.39E-08	1.344495518	1.098756658	-0.291193039
145	Sinularin_1838	8.53E-08	5.279113787	5.11655461	-0.045123108

Table S3 (*continued*)

https://dx.doi.org/10.21037/tcr-24-1826

Table S3 (*continued*)

	CheckPoint	pvalue.w.check	Low_risk	High_risk	logfc
170	I-BRD9_1928	1.15E-07	6.463359732	6.187519632	-0.062923093
167	GDC0810_1925	1.48E-07	7.18636867	7.020329175	-0.033724271
76	Cyclophosphamide_1512	1.50E-07	7.558818223	7.367804704	-0.036925874
114	ERK_2440_1713	1.73E-07	3.880283959	3.963712979	0.030690265
131	Carmustine_1807	2.06E-07	8.919134124	8.719702062	-0.032624818
3	Cisplatin_1005	1.00E-06	5.024042092	4.522898045	-0.151601076
50	MK-1775_1179	1.25E-06	1.675493466	1.45409746	-0.204462093
142	Dihydrorotenone_1827	1.74E-06	1.855938021	1.713313634	-0.115359261
15	Afatinib_1032	2.10E-06	2.963270495	2.708428093	-0.129734537
181	BPD-00008900_1998	2.43E-06	6.679946144	6.448981611	-0.050765115
116	IRAK4_4710_1716	3.56E-06	7.249373613	7.036177391	-0.043064488
183	BIBR-1532_2043	6.96E-06	7.253046387	7.073574025	-0.036147734
160	AZD3759_1915	1.07E-05	4.080385528	3.841863467	-0.08689922
59	YK-4-279_1239	1.16E-05	3.609256486	3.307867383	-0.125800274
172	MIRA-1_1931	2.01E-05	7.950642073	7.708974405	-0.044532435
51	Dinaciclib_1180	2.24E-05	0.113595229	0.100588993	-0.1754298
13	SB216763_1025	2.91E-05	7.499294472	7.645515543	0.027858913
185	AMG-319_2045	3.35E-05	7.166120529	6.910447368	-0.052413198
169	GSK2578215A_1927	4.22E-05	7.187828605	7.017283803	-0.034643297
56	Tamoxifen_1199	4.76E-05	5.257821641	5.14078827	-0.032475609
146	Sabutoclax_1849	5.50E-05	0.72966943	0.777506843	0.091612359
188	Vinorelbine_2048	5.84E-05	0.094262245	0.083744732	-0.170681604
101	RVX-208_1625	6.01E-05	6.954440514	6.803280042	-0.031703979
69	IAP_5620_1428	7.05E-05	7.532192227	7.266467292	-0.051815673
157	Dactinomycin_1911	7.60E-05	0.015270801	0.012890169	-0.244504532
149	MN-64_1854	8.15E-05	6.904727462	6.745131828	-0.033737831
2	Vinblastine_1004	9.47E-05	0.045071651	0.04068482	-0.147729689
155	Venetoclax_1909	0.000102671	3.420681103	3.189735123	-0.100846987
54	GSK269962A_1192	0.000103942	4.17757324	4.298828572	0.041278458
193	GSK591_2110	0.00010903	6.710758788	6.524453002	-0.040618948
159	AGI-5198_1913	0.000181659	6.785216356	6.665294944	-0.025726102
162	AZD6738_1917	0.000214167	3.321019814	3.062215721	-0.117050412
129	Acetalax_1804	0.000310213	7.092805008	6.821709141	-0.056223043
140	Docetaxel_1819	0.000343125	0.224137601	0.212353539	-0.077916545

Table S3 (*continued*)

https://dx.doi.org/10.21037/tcr-24-1826

Table S3 (*continued*)

	CheckPoint	pvalue.w.check	Low_risk	High_risk	logfc
152	BDP-00009066_1866	0.000395414	3.649455177	3.489465112	-0.064675194
16	Staurosporine_1034	0.00069754	0.097977032	0.086467199	-0.18029063
57	Fulvestrant_1200	0.000826773	4.336991977	4.235728456	-0.03408467
85	EPZ5676_1563	0.000894604	8.099368418	7.937132123	-0.029191591
125	JAK_8517_1739	0.001078483	4.315701752	4.504642403	0.061817417
77	Pevonedistat_1529	0.001121056	1.769789065	1.607519688	-0.138741014
97	PFI3_1620	0.001121056	7.652651267	7.533922535	-0.022558458
194	VE821_2111	0.001195479	6.126878361	5.80219982	-0.078552228
91	LGK974_1598	0.001270015	5.915477238	5.771916054	-0.035444247
89	Entinostat_1593	0.001284831	3.402908236	3.243230199	-0.06933682
120	TAF1_5496_1732	0.001325637	5.646827048	5.4831601	-0.042432846
134	Mitoxantrone_1810	0.001587571	1.523593031	1.674613093	0.136350217
187	Ulixertinib_2047	0.001730786	3.41689884	3.27821429	-0.059777373
98	PCI-34051_1621	0.002083482	6.483181529	6.571898511	0.019608232
168	GNE-317_1926	0.002106843	1.419057065	1.495529638	0.075723896
164	Osimertinib_1919	0.002539764	2.804739063	2.674436356	-0.068631685
65	Trametinib_1372	0.002650585	1.464421577	1.676729073	0.19531866
24	ZM447439_1050	0.003431857	4.397905228	4.337597599	-0.019920295
196	AT13148_2170	0.004049346	5.429335366	5.211022767	-0.059209043
112	CDK9_5038_1709	0.004562588	0.171040997	0.160495578	-0.091808625
106	PRT062607_1631	0.005273141	4.718550247	4.824662385	0.032084324
171	Telomerase Inhibitor IX_1930	0.005917959	1.442592092	1.37806898	-0.066015316
113	Eg5_9814_1712	0.006501049	0.078972905	0.074910644	-0.076187022
156	ABT737_1910	0.007329582	3.435166484	3.216442512	-0.094914117
126	AZD4547_1786	0.00741008	4.301870542	4.196184734	-0.035885917
104	ML323_1629	0.007894356	6.501562147	6.412204583	-0.019965944
110	AZD5153_1706	0.008292219	2.64169942	2.776838852	0.071977133
61	BMS-345541_1249	0.008514443	4.956673158	4.828410621	-0.037823759
4	Cytarabine_1006	0.009660687	2.865137435	2.649003292	-0.113154707
63	Talazoparib_1259	0.00995356	4.824662345	4.553778779	-0.083363771
67	Temozolomide_1375	0.010382829	8.730704842	8.574284892	-0.026081776
141	Podophyllotoxin bromide_1825	0.011068157	0.66080474	0.625356102	-0.079546084
94	CZC24832_1615	0.012108739	7.391514794	7.262475575	-0.02540865
117	JAK1_8709_1718	0.013002701	6.005921618	6.092038786	0.02053948

Table S3 (*continued*)

https://dx.doi.org/10.21037/tcr-24-1826

Table S3 (*continued*)

	CheckPoint	pvalue.w.check	Low_risk	High_risk	logfc
37	Crizotinib_1083	0.014045241	4.800443721	4.611469586	-0.057941182
33	Obatoclax Mesylate_1068	0.016473046	2.328836167	2.387763245	0.036050645
111	CDK9_5576_1708	0.020261325	0.846973687	0.793335722	-0.094385639
148	OF-1_1853	0.020640738	5.988466241	5.887316455	-0.024576371
143	Gallibiscoquinazole_1830	0.022085415	3.888693024	3.827051205	-0.023052148
23	PD173074_1049	0.022711202	5.988735333	5.826086495	-0.039724255
79	Uprosertib_1553	0.023433576	4.321250634	4.434340457	0.037270631
10	Olaparib_1017	0.025392698	6.328228302	6.168338737	-0.036919655
90	OSI-027_1594	0.025523823	6.710756864	6.690094086	-0.004448988
144	Elephantin_1835	0.027867857	4.996888207	5.079758704	0.023730027
191	LJI308_2107	0.028415929	7.436369201	7.29853828	-0.026990843
29	Dactolisib_1057	0.029243122	0.29266492	0.311057456	0.087931262
38	Rapamycin_1084	0.035169997	0.185911025	0.174477068	-0.091574897
93	WZ4003_1614	0.035663401	5.400687301	5.504125957	0.027370466
43	BMS-536924_1091	0.040149181	3.213950223	3.292856623	0.03499211
108	AGI-6780_1634	0.040149181	6.011701711	5.937669729	-0.017876579
45	Tozasertib_1096	0.04079945	4.327896111	4.165123202	-0.055306698
49	Niraparib_1177	0.044997871	6.219320998	6.273576527	0.012531068
147	LY2109761_1852	0.046916195	7.43679731	7.484439961	0.009212916
139	Vincristine_1818	0.047471448	0.288366149	0.277617491	-0.054803353
92	VE-822_1613	0.048295807	5.028075641	4.785489098	-0.071339971
124	IGF1R_3801_1738	0.050253159	2.692776536	2.814712341	0.063892978
75	Epirubicin_1511	0.05567249	0.507781337	0.477491426	-0.088732544
68	AZD5438_1401	0.060925974	3.506570643	3.364670205	-0.05959569
137	Nelarabine_1814	0.066435892	8.750495389	8.645387053	-0.017434139
14	KU-55933_1030	0.075191925	6.337392357	6.255801533	-0.018694594
195	AZD6482_2169	0.077229531	4.547734902	4.593320119	0.014389173
96	GSK2606414_1618	0.079482728	5.39757828	5.460228436	0.016649048
18	NU7441_1038	0.086747989	3.826834484	3.869440941	0.015973636
122	VSP34_8731_1734	0.088785854	3.620348634	3.527673382	-0.037411642
115	ERK_6604_1714	0.091690691	4.932740997	5.036301869	0.029975221
73	Ruxolitinib_1507	0.094540224	7.043974728	6.944142973	-0.020593081
82	Luminespib_1559	0.108471266	0.180819616	0.169544484	-0.092887341
8	Vorinostat_1012	0.111503145	2.415256084	2.364884858	-0.03040622

Table S3 (*continued*)

https://dx.doi.org/10.21037/tcr-24-1826

Table S3 (*continued*)

	CheckPoint	pvalue.w.check	Low_risk	High_risk	logfc
52	Gemcitabine_1190	0.111503145	0.865392119	0.821486089	-0.075117837
161	AZD5363_1916	0.127926614	4.399425216	4.291448979	-0.035850202
136	Fludarabine_1813	0.129012455	7.343171967	7.209612202	-0.026481726
86	SCH772984_1564	0.142426488	3.814237671	3.902799624	0.033114651
60	Daporinad_1248	0.15610876	0.020396478	0.02081485	0.029293123
26	RO-3306_1052	0.168493533	4.482135959	4.493920036	0.003788042
28	Palbociclib_1054	0.180517171	5.272259331	5.333957775	0.016785069
153	Buparlisib_1873	0.19112721	1.884166807	1.860122677	-0.018528922
132	Topotecan_1808	0.197062526	1.161530495	1.212745447	0.062249732
158	Afuresertib_1912	0.197524617	3.827062944	3.730865594	-0.036727242
100	I-BET-762_1624	0.205501843	4.897477179	4.811253934	-0.025625824
58	EPZ004777_1237	0.220270837	7.490699166	7.418049344	-0.014060519
192	AZ6102_2109	0.240681337	3.646621731	3.679246809	0.012849903
150	KRAS (G12C) Inhibitor-12_1855	0.248907217	6.387682874	6.304026281	-0.01901914
17	PLX-4720_1036	0.276219968	6.442954208	6.491593384	0.010850295
135	Dactinomycin_1811	0.316943734	0.125737185	0.128199624	0.02798066
30	Pictilisib_1058	0.333951003	2.420450242	2.37025205	-0.030234955
166	Ipatasertib_1924	0.343856257	5.155819337	5.085875932	-0.019705443
27	MK-2206_1053	0.349135119	4.436701768	4.465813118	0.0094353
154	Ulixertinib_1908	0.353947114	4.059980824	4.105282542	0.016008604
102	OTX015_1626	0.374147254	3.705179436	3.738285779	0.012833451
34	5-Fluorouracil_1073	0.381879991	6.886017427	6.774062516	-0.023648531
35	Dasatinib_1079	0.382423118	2.759988869	2.690405589	-0.036838768
64	XAV939_1268	0.384963967	6.399540579	6.335475989	-0.014515324
66	Dabrafenib_1373	0.393016444	6.64332098	6.646813783	0.000758314
109	Picolinici-acid_1635	0.417779246	7.421169425	7.426204693	0.000978538
189	VX-11e_2096	0.427781281	4.137626597	4.183549059	0.015923899
1	Camptothecin_1003	0.430109088	0.160504123	0.160847142	0.003079937
44	GSK1904529A_1093	0.440674822	6.235290985	6.242119897	0.00157918
84	Taselisib_1561	0.457805146	3.198188384	3.235720793	0.016832204
133	Teniposide_1809	0.488350427	1.520423861	1.547442553	0.02541228
103	GSK343_1627	0.510518535	4.144288207	4.146301779	0.000700787
182	Foretinib_2040	0.523418258	1.918017187	1.944379249	0.019693995
138	Fulvestrant_1816	0.54351764	6.534290807	6.548747944	0.003188441

Table S3 (*continued*)

https://dx.doi.org/10.21037/tcr-24-1826

Table S3 (*continued*)

	CheckPoint	pvalue.w.check	Low_risk	High_risk	logfc
25	Alisertib_1051	0.550375752	3.056024682	3.022363736	-0.015978899
105	Entospletinib_1630	0.554600067	5.425029336	5.429903419	0.001295598
87	IWP-2_1576	0.559734833	4.118070606	4.075810772	-0.014881493
74	Linsitinib_1510	0.57414302	5.515582177	5.453717097	-0.016273307
32	PD0325901_1060	0.601390405	1.469575892	1.498735198	0.02834564
55	SB505124_1194	0.614411472	3.395016978	3.387677502	-0.003122249
165	Cediranib_1922	0.619326184	3.274534383	3.279389035	0.00213728
88	Leflunomide_1578	0.644867549	7.239813114	7.193324427	-0.009293784
22	Mirin_1048	0.660205934	6.883414078	6.879593987	-0.000800875
119	PAK_5339_1730	0.684947053	3.600255249	3.571349485	-0.011629874
130	Oxaliplatin_1806	0.684947053	7.233847073	7.211751754	-0.004413362
11	Axitinib_1021	0.697693567	4.480509751	4.485260425	0.001528876
83	Alpelisib_1560	0.738441073	5.172819759	5.179776041	0.001938798
7	Navitoclax_1011	0.740448782	3.016694353	3.001530627	-0.007270143
184	Pyridostatin_2044	0.742206979	4.911370024	4.872250076	-0.011537336
99	Wnt-C59_1622	0.770261212	6.123007234	6.114294678	-0.002054303
190	Uprosertib_2106	0.833466874	4.163355442	4.114525522	-0.017020661
163	AZD8186_1918	0.842558059	4.820744218	4.80490088	-0.004749214
173	NVP-ADW742_1932	0.845940204	4.083083425	4.072933074	-0.003590936
39	Sorafenib_1085	0.853755898	3.92804305	3.91079725	-0.006347998
9	Nilotinib_1013	0.907508546	5.228654386	5.210043627	-0.005144258
46	PF-4708671_1129	0.913306875	5.587924359	5.587543554	-9.83E-05
41	Irinotecan_1088	0.915944024	3.900774745	3.875115321	-0.009521446
71	AZD1208_1449	0.931256826	7.678273823	7.631469248	-0.008821172
42	Oxaliplatin_1089	0.934692704	5.446776283	5.418019832	-0.007636938
62	AZ960_1250	0.958509464	3.198154727	3.169608221	-0.012935211
128	Zoledronate_1802	0.980772335	5.502828527	5.460371567	-0.011174247

https://dx.doi.org/10.21037/tcr-24-1826